Bioalpha Holdings Berhad

RM 0.02As of Sun 8 Nov 2026, 12:00 UTC

KLSE:BIOHLDGHealthcare

Country Malaysia

PE (Fwd) •••

TSR 10Y CAGR (21.78%)

Div yield —

ROE (27.65%)

Pharmaceutical Preparations

Beta (5Y) 0.48

PE TTM —

TSR TTM —

Mkt cap RM 28.39M

ROIC (63.66%)

SE Grade™

Value

Quality

Moat

Consensus

Reference

RM 0.0258

29.17%

(72.22%)

Sell 2|4|1|5|9

TTM

FYE 31 Dec MYR

FY2016

FY2017

FY2018

FY2019

FY2020

FY2021

FY2022

FY2023

FY2024

FY2025

FY2026E

Trend

5Y

10Y

Peers

1.092

RevenueRM M

3.821

4.091

4.286

4.542

4.808

5.083

5.235

5.618

6.045

6.238

1.202

5.35%

5.74%

5

16.87

Revenue growth%

21.22

23.67

24.32

26.15

26.83

25.25

27.86

26.19

26.93

28.93

3.98

26.93

26.17

14

22.62

Gross margin%

4.29

3.60

2.83

3.07

0.64

3.14

5.17

4.28

5.33

5.06

2.80

5.06

3.94

18

19.36

Operating margin%

28.72

28.43

28.34

26.51

24.12

22.92

20.71

21.14

22.45

24.48

12.08

22.45

24.30

34

25.04

Net margin%

29.02

28.05

29.92

27.98

30.22

29.96

29.86

30.46

30.25

31.03

17.50

30.25

29.94

21

34.08

P/E ratio (avg)x

10.77

9.577

10.24

8.759

8.208

8.182

7.251

6.789

6.466

6.525

18.52

6.789

8.195

77

30.72

EV/EBITx

52.34

51.83

52.37

52.96

50.43

51.40

54.85

63.08

64.12

63.82

7.113

63.08

52.67

66

11.76

FCF yield (avg)%

26.83

25.96

27.51

27.08

27.99

28.74

26.21

25.51

25.58

22.95

5.42

25.58

26.52

49

11.18

FCF margin%

12.66

10.61

10.61

9.54

7.42

5.10

2.30

0.54

3.00

1.16

14.03

2.30

6.26

51

0.112

FCF / Net incomex

0.359

0.353

0.363

0.436

0.488

0.519

0.605

0.612

0.617

0.718

1.435

0.612

0.503

8

18.76

ROIC%

18.67

21.63

20.12

18.50

19.45

20.58

21.14

20.80

23.40

24.08

7.07

21.14

20.69

70

21.68

Return on equity%

24.04

22.86

20.02

21.54

23.70

24.40

22.86

23.02

21.37

22.86

18.28

22.86

22.86

49

9.29

Return on assets%

11.44

9.57

7.82

6.62

8.37

8.63

7.71

10.47

11.18

8.19

22.56

8.63

8.50

64

—

EPSRM

—

—

—

—

—

—

—

—

—

—

—

(0.24%)

3.59%

—

26.38

EPS growth%

1.50

1.36

2.72

1.01

1.46

3.32

3.39

4.03

3.12

0.93

2.15

3.32

2.11

51

—

Bookvalue per shRM

—

—

—

—

—

—

—

—

—

—

—

1.24%

1.66%

—

—

FCF per shareRM

—

—

—

—

—

—

—

—

—

—

—

2.11%

2.41%

—

—

Dividend per shRM

—

—

—

—

—

—

—

—

—

—

—

6.48%

4.64%

—

16.84

Div yield (avg)%

9.30

8.51

6.93

9.65

7.11

7.55

8.78

6.36

6.02

8.79

20.15

7.55

8.03

12

16.68

Payout ratio%

10.62

10.37

11.93

9.56

6.75

6.45

6.30

4.10

2.08

4.19

5.48

4.19

6.60

42

1.406

Shares (diluted)B

1.401

1.330

1.200

1.234

1.210

1.206

1.202

1.326

1.280

1.188

1.393

(0.38%)

(1.97%)

29

19.20

Buyback yield%

17.87

15.33

15.81

16.39

13.69

14.85

15.48

17.11

14.49

14.61

24.10

14.85

15.41

10

1.095

D/E ratiox

1.160

1.122

1.215

1.278

1.430

1.520

1.719

1.844

2.028

2.205

0.498

1.844

1.475

87

6.188

Enterprise valueRM M

1.026

1.102

0.989

0.889

0.965

1.014

1.046

1.001

1.035

1.107

5.740

2.79%

0.43%

58

2.143

LT debtRM M

2.221

2.102

2.297

2.140

2.073

1.811

1.699

1.760

1.801

1.971

1.786

(1.00%)

(2.23%)

33

Peers (US$6.999M)

Cap (US$)

PE

Rhone Ma Holdings…

37.37M

12.38x

Nova Wellness Group…

30.25M

14.38x

PeterLabs Holdings…

16.28M

—

ChoA Pharmaceutical…

7.154M

—

Capital

TTM

5Y

10Y

Leveragex

5.296

(0.702)

(0.643)

EBIT/Intx

0.814

0.753

0.683

Own earn%

(216.06)

(35.73)

(50.48)

Sh yield%

36.04

23.40

23.44

Owners

Insiders/Inst%

8.48

79.76

Short interest%

3.22

SBC / revenue%

1.49

Record

10Y

Profitable years

10/10

Revenue growth years

10/10

EPS growth years

10/10

Dividend streakyrs

10

Op margin range%

21–29

$1 testx

—

Incr. ROIC%

3

Growth vs revenue

Latest

Trend

10Y CAGR

Rel growth

Revenue

RM 6.238M

5.74%

1.00×

Cost of revenue

RM 4.367M

5.74%

1.00×

Operating expenses

RM 0.866M

5.99%

1.02×